A Phase 3 interventional study of fluticasone propionate (FP) and fluticasone furoate (FF) in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 12 in phase 3, and was the 9th registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is close to the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 288 across the 21 interventional studies. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 28 finished, 13 (46%) have results posted.
Among the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline, this one is the 14th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2006, is one of 16 in phase 3, and was the 13th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Perennial studies by the year they started, since 2005.
1 of the studies testing fluticasone in Rhinitis, Allergic, Perennial that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07817134HALEONA Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 28 in Rhinitis, Allergic, Perennial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate and compare patient preference for FF (Fluticasone Furoate) and FP (Fluticasone Propionate Aqueous)nasal sprays in the treatment of allergic rhinitis following single-dose administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 micrograms (mcg); an aqueous suspension of microfine FP
Drug: fluticasone propionate (FP)
110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
Drug: fluticasone furoate (FF)
200 micrograms (mcg); an aqueous suspension of microfine FP
110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
Also known as: fluticasone furoate, fluticasone propionate
Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing
An overall preference questionnaire (OPQ) was used to evaluate participant's preference for nasal spray therapy for the given treatments. OPQ allows the responder three options, based on products attributes, i.e. preference for product 1 (FF 110 µg); preference for product 2 (FP 200 µg) and no preference. Three participant-related questionnaires were completed during the course of the study, including two attributes questionnaires : Immediate attributes questionnaire (IAQ) and delayed attributes questionnaire (DAQ). An OPQ was completed upon completion of the crossover dosing.
Time frame: Day 1
Number of Participants With Preference for Scent/Odor in IAQ and DAQ
Participant preference for scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product have a scent/odor?. Participants specified their responses on a 6-point scale: 0: none; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong. Higher score indicated strong odor.
Time frame: Day 1
Number of Participants With Preference for Satisfaction With Scent/Odor in IAQ
Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants With Preference for Satisfaction With Scent/Odor in DAQ
Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants Who Satisfied Not to Have Scent/Odor in IAQ
Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants Who Satisfied Not to Have Scent/Odor in DAQ
Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants Reported Product Have an Immediate Taste in IAQ
Participant preference for an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product have an immediate taste?. Participants specified their responses on a on a 6-point scale: 0: no; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong.
Time frame: Day 1
Number of Participants Satisfied With an Immediate Taste in IAQ
Participant preference for satisfaction with an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with immediate taste?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants Reported Product Have an After Taste in DAQ
Participant response for an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product have an aftertaste?. Participants specified their responses on a 6-point scale: 0: No aftertaste; 1: Very mild; 2: Mild; 3: Neither mild nor strong; 4: Slightly strong; 5: Moderately strong; 6: Very strong.
Time frame: Day 1
Number of Participants Satisfied With an After Taste in DAQ
Participant response for satisfaction with an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How satisfied with aftertaste? Participants specified their responses on a 6-point scale: 0: Very satisfied; 1: Moderately satisfied; 2: Somewhat satisfied; 3: Neither satisfied nor dissatisfied; 4: Somewhat dissatisfied; 5: Moderately dissatisfied; 6: Very dissatisfied.
Time frame: Day 1
Number of Participants Reported Medicine Run Down Throat in IAQ and DAQ
Participant response regarding did the medicine run down throat at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run down throat? Participants specified their responses on a 6-point scale: 0: None; 1: Very slightly; 2: Slightly; 3: Neither slightly nor moderately; 4: Moderately; 5: Markedly; 6: Very markedly.
Time frame: Day 1
Number of Participants Reported Medicine Run Out of Nose in IAQ and DAQ
Participant response regarding did the medicine run out of nose at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run out of nose? Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
Time frame: Day 1
Number of Participants Reported Product Feel Soothing in IAQ and DAQ
Participant response for soothing feel at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product feel soothing?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
Time frame: Day 1
Number of Participants Reported Product Make Want to Sneeze in IAQ
Participant response regarding sneezing effect at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product make want to sneeze?. Participants specified their responses on a 6-point scale: 0: No urgency; 1: Very slight urgency; 2: slight urgency; 3: Neither slight nor moderate urgency; 4: Moderate urgency; 5; Marked urgency; 6: Very marked urgency.
Time frame: Day 1
Number of Participants Satisfied With Product in DAQ
Number of participants responding to product satisfaction with delayed attributes questionnaire, Question: How satisfied with product?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
Time frame: Day 1
Number of Participants Reported Nasal Irritation in DAQ
Participant response regarding nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product cause nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slight; 2: slight; 3: neither slight nor moderate; 4: moderate; 5; marked; 6: very marked.
Time frame: Day 1
Number of Participants Reported Nasal Irritation Bothersome in DAQ
Participant response regarding bothersome of nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How bothersome was nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
Time frame: Day 1
Number of Participants Comply With Product if Prescribed in DAQ
Number of participants responding to product attributes using delayed attributes questionnaire, Question: How likely to comply if prescribed?. Participants specified their responses on a 6-point scale: 0: very likely; 1: moderately likely; 2: somewhat likely; 3: neither likely nor unlikely; 4: somewhat unlikely; 5; moderately unlikely; 6: very unlikely.
Time frame: Day 1
A total of 127 male or eligible female participants with a diagnosis of allergic rhinitis were enrolled in the study. This study was conducted at 12 investigator sites in the United States. Study duration was '01 December 2006 - 04 December 2006'. Participants included in PP population were 121.
| Milestone | FF 110 µg /FP 200 µg | FP 200 µg /FF 110 µg |
|---|---|---|
| Started | 63 | 64 |
| Completed | 63 | 64 |
| Not completed | 0 | 0 |
| Milestone | FF 110 µg /FP 200 µg | FP 200 µg /FF 110 µg |
|---|---|---|
| Started | 63 | 64 |
| Completed | 63 | 64 |
| Not completed | 0 | 0 |
| Milestone | FF 110 µg /FP 200 µg | FP 200 µg /FF 110 µg |
|---|---|---|
| Started | 63 | 64 |
| Completed | 63 | 64 |
| Not completed | 0 | 0 |
An overall preference questionnaire (OPQ) was used to evaluate participant's preference for nasal spray therapy for the given treatments. OPQ allows the responder three options, based on products attributes, i.e. preference for product 1 (FF 110 µg); preference for product 2 (FP 200 µg) and no preference. Three participant-related questionnaires were completed during the course of the study, including two attributes questionnaires : Immediate attributes questionnaire (IAQ) and delayed attributes questionnaire (DAQ). An OPQ was completed upon completion of the crossover dosing.
| Participants | Overall Study Arm |
|---|---|
| Overall, FF 110 µg | 72 |
| Overall, FP 200 µg | 39 |
| Overall, No preference | 9 |
| Scent/odor, FF 110 µg | 77 |
| Scent/odor, FP 200 µg | 35 |
| Scent/odor, No preference | 8 |
| Immediate taste, FF 110 µg | 56 |
| Immediate taste, FP 200 µg | 25 |
| Immediate taste, No preference | 39 |
| After-taste, FF 110 µg | 53 |
| After-taste, FP 200 µg | 26 |
| After-taste, No preference | 41 |
| Less drip down throat, FF 110 µg | 52 |
| Less drip down throat, FP 200 µg | 32 |
| Less drip down throat, No preference | 36 |
| Less run out nose, FF 110 µg | 59 |
| Less run out nose, FP 200 µg | 23 |
| Less run out nose, No preference | 38 |
| More soothing, FF 110 µg | 45 |
| More soothing, FP 200 µg | 38 |
| More soothing, No preference | 37 |
| Less irritating, FF 110 µg | 41 |
| Less irritating, FP 200 µg | 26 |
| Less irritating, No preference | 53 |
| Urge to sneeze, FF 110 µg | 25 |
| Urge to sneeze, FP 200 µg | 21 |
| Urge to sneeze, No preference | 74 |
Participant preference for scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product have a scent/odor?. Participants specified their responses on a 6-point scale: 0: none; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong. Higher score indicated strong odor.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, None | 62 | 12 |
| DAQ, None | 71 | 16 |
| IAQ, Very mild | 27 | 22 |
| DAQ, Very mild | 21 | 39 |
| IAQ, Mild | 19 | 35 |
| DAQ, Mild | 16 | 29 |
| IAQ, Neither mild nor strong | 2 | 7 |
| DAQ, Neither mild nor strong | 4 | 4 |
| IAQ, Slightly strong | 6 | 20 |
| DAQ, Slightly strong | 6 | 20 |
| IAQ, Moderately strong | 4 | 19 |
| DAQ, Moderately strong | 2 | 10 |
| IAQ, Very strong | 1 | 5 |
| DAQ, Very strong | 1 | 3 |
Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, Very satisfied | 11 | 16 |
| IAQ, Moderately satisfied | 12 | 20 |
| IAQ, Somewhat satisfied | 13 | 25 |
| IAQ, Neither satisfied nor dissatisfied | 16 | 17 |
| IAQ, Somewhat dissatisfied | 6 | 23 |
| IAQ, Moderately dissatisfied | 1 | 5 |
| IAQ, Very dissatisfied | 2 | 3 |
Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| DAQ, Very satisfied | 14 | 19 |
| DAQ, Moderately satisfied | 11 | 21 |
| DAQ, Somewhat satisfied | 12 | 20 |
| DAQ, Neither satisfied nor dissatisfied | 10 | 22 |
| DAQ, Somewhat dissatisfied | 5 | 16 |
| DAQ, Moderately dissatisfied | 0 | 6 |
| DAQ, Very dissatisfied | 1 | 2 |
Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, Very satisfied | 46 | 10 |
| IAQ, Moderately satisfied | 7 | 2 |
| IAQ, Somewhat satisfied | 1 | 0 |
| IAQ, Neither satisfied nor dissatisfied | 6 | 1 |
| IAQ, Somewhat dissatisfied | 2 | 0 |
| IAQ, Moderately dissatisfied | 0 | 0 |
| IAQ, Very dissatisfied | 1 | 1 |
Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| DAQ, Very satisfied | 56 | 14 |
| DAQ, Moderately satisfied | 2 | 1 |
| DAQ, Somewhat satisfied | 4 | 0 |
| DAQ, Neither satisfied nor dissatisfied | 8 | 1 |
| DAQ, Somewhat dissatisfied | 3 | 0 |
| DAQ, Moderately dissatisfied | 0 | 0 |
| DAQ, Very dissatisfied | 1 | 0 |
Participant preference for an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product have an immediate taste?. Participants specified their responses on a on a 6-point scale: 0: no; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| No taste | 98 | 69 |
| Very mild taste | 10 | 25 |
| Mild taste | 7 | 13 |
| Neither mild nor strong taste | 2 | 6 |
| Slightly strong taste | 3 | 6 |
| Moderately strong taste | 1 | 2 |
| Very strong taste | 0 | 0 |
Participant preference for satisfaction with an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with immediate taste?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| Very satisfied | 6 | 12 |
| Moderately satisfied | 7 | 9 |
| Somewhat satisfied | 6 | 9 |
| Neither satisfied nor dissatisfied | 9 | 15 |
| Somewhat dissatisfied | 3 | 6 |
| Moderately dissatisfied | 1 | 3 |
| Very dissatisfied | 1 | 0 |
Participant response for an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product have an aftertaste?. Participants specified their responses on a 6-point scale: 0: No aftertaste; 1: Very mild; 2: Mild; 3: Neither mild nor strong; 4: Slightly strong; 5: Moderately strong; 6: Very strong.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| No aftertaste | 90 | 66 |
| Very mild aftertaste | 22 | 33 |
| Mild aftertaste | 7 | 10 |
| Neither mild nor strong aftertaste | 0 | 3 |
| Slightly strong aftertaste | 2 | 6 |
| Moderately strong aftertaste | 0 | 3 |
| Very strong aftertaste | 0 | 0 |
Participant response for satisfaction with an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How satisfied with aftertaste? Participants specified their responses on a 6-point scale: 0: Very satisfied; 1: Moderately satisfied; 2: Somewhat satisfied; 3: Neither satisfied nor dissatisfied; 4: Somewhat dissatisfied; 5: Moderately dissatisfied; 6: Very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| Very satisfied | 7 | 12 |
| Moderately satisfied | 8 | 9 |
| Somewhat satisfied | 3 | 7 |
| Neither satisfied nor dissatisfied | 11 | 15 |
| Somewhat dissatisfied | 3 | 9 |
| Moderately dissatisfied | 2 | 2 |
| Very dissatisfied | 0 | 0 |
Participant response regarding did the medicine run down throat at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run down throat? Participants specified their responses on a 6-point scale: 0: None; 1: Very slightly; 2: Slightly; 3: Neither slightly nor moderately; 4: Moderately; 5: Markedly; 6: Very markedly.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, None | 74 | 69 |
| DAQ, None | 64 | 55 |
| IAQ, Very slightly | 28 | 29 |
| DAQ, Very slightly | 36 | 37 |
| IAQ, Slightly | 11 | 15 |
| DAQ, Slightly | 12 | 17 |
| IAQ, Neither slightly nor moderately | 3 | 5 |
| DAQ, Neither slightly nor moderately | 1 | 3 |
| IAQ, Moderately | 3 | 3 |
| DAQ, Moderately | 5 | 6 |
| IAQ, Markedly | 1 | 0 |
| DAQ, Markedly | 3 | 1 |
| IAQ, Very markedly | 1 | 0 |
| DAQ, Very markedly | 0 | 1 |
Participant response regarding did the medicine run out of nose at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run out of nose? Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, None | 61 | 38 |
| DAQ, None | 63 | 46 |
| IAQ, Very slightly | 42 | 38 |
| DAQ, Very slightly | 40 | 39 |
| IAQ, Slightly | 11 | 28 |
| DAQ, Slightly | 10 | 24 |
| IAQ, Neither slightly nor moderately | 2 | 1 |
| DAQ, Neither slightly nor moderately | 1 | 1 |
| IAQ, Moderately | 5 | 11 |
| DAQ, Moderately | 7 | 4 |
| IAQ, Markedly | 0 | 4 |
| DAQ, Markedly | 0 | 4 |
| IAQ, Very markedly | 0 | 1 |
| DAQ, Very markedly | 0 | 3 |
Participant response for soothing feel at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product feel soothing?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| IAQ, None | 28 | 24 |
| DAQ, None | 26 | 25 |
| IAQ, Very slight | 28 | 31 |
| DAQ, Very slight | 34 | 31 |
| IAQ, Slight | 25 | 27 |
| DAQ, Slight | 25 | 29 |
| IAQ, Neither slight nor moderate | 17 | 16 |
| DAQ, Neither slight nor moderate | 15 | 11 |
| IAQ, Moderate | 15 | 16 |
| DAQ, Moderate | 11 | 19 |
| IAQ, Marked | 4 | 5 |
| DAQ, Marked | 5 | 6 |
| IAQ, Very marked | 4 | 2 |
| DAQ, Very marked | 4 | 0 |
Participant response regarding sneezing effect at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product make want to sneeze?. Participants specified their responses on a 6-point scale: 0: No urgency; 1: Very slight urgency; 2: slight urgency; 3: Neither slight nor moderate urgency; 4: Moderate urgency; 5; Marked urgency; 6: Very marked urgency.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| No urgency | 87 | 93 |
| Very slight urgency | 17 | 12 |
| Slight urgency | 8 | 10 |
| Neither slight nor moderate urgency | 2 | 2 |
| Moderate urgency | 2 | 2 |
| Marked urgency | 3 | 2 |
| Very marked urgency | 2 | 0 |
Number of participants responding to product satisfaction with delayed attributes questionnaire, Question: How satisfied with product?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| Very satisfied | 44 | 34 |
| Moderately satisfied | 27 | 23 |
| Somewhat satisfied | 17 | 27 |
| Neither satisfied nor dissatisfied | 19 | 21 |
| Somewhat dissatisfied | 7 | 8 |
| Moderately dissatisfied | 5 | 7 |
| Very dissatisfied | 2 | 0 |
Participant response regarding nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product cause nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slight; 2: slight; 3: neither slight nor moderate; 4: moderate; 5; marked; 6: very marked.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| None | 89 | 78 |
| Very slight | 18 | 21 |
| Slight | 6 | 10 |
| Neither slight nor moderate | 2 | 3 |
| Moderate | 3 | 7 |
| Marked | 2 | 1 |
| Very marked | 1 | 1 |
Participant response regarding bothersome of nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How bothersome was nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| None | 7 | 7 |
| Very slightly | 15 | 22 |
| Slightly | 9 | 8 |
| Neither slightly nor moderately | 2 | 2 |
| Moderately | 4 | 6 |
| Markedly | 0 | 1 |
| Very markedly | 1 | 2 |
Number of participants responding to product attributes using delayed attributes questionnaire, Question: How likely to comply if prescribed?. Participants specified their responses on a 6-point scale: 0: very likely; 1: moderately likely; 2: somewhat likely; 3: neither likely nor unlikely; 4: somewhat unlikely; 5; moderately unlikely; 6: very unlikely.
| Participants | FF 110 µg | FP 200 µg |
|---|---|---|
| Very likely | 63 | 45 |
| Moderately likely | 19 | 26 |
| Somewhat likely | 18 | 16 |
| Neither likely nor unlikely | 7 | 10 |
| Slightly unlikely | 4 | 12 |
| Moderately unlikely | 4 | 7 |
| Very unlikely | 6 | 4 |
Collected over Adverse events were reported throughout the treatment period (Day 1), as this is single day study which included pre treatment, washout, treatment periods 1 and 2. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF 110 µg | 0/127 (0%) | 0/127 (0%) | 3/127 (2.4%) |
| FP 200 µg | 0/127 (0%) | 0/127 (0%) | 0/127 (0%) |
| Event | FF 110 µg | FP 200 µg |
|---|---|---|
| DizzinessNervous system disorders | 1/127 | 0/127 |
| HeadacheNervous system disorders | 1/127 | 0/127 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/127 | 0/127 |
| Age, Continuous(Years) | Overall Study Arm |
|---|---|
| Mean | 39.7 ± 14.05 |
| Sex: Female, Male(Participants) | Overall Study Arm |
|---|---|
| Female | 82 |
| Male | 45 |
| Race/Ethnicity, Customized(Participants) | Overall Study Arm |
|---|---|
| Race — African American/African Heritage | 20 |
| Race — Asian - East Asian Heritage | 1 |
| Race — Asian - South East Asian Heritage | 1 |
| Race — Native Hawaiian or other Pacific Islander | 1 |
| Race — White - Arabic/North African Heritage | 1 |
| Race — White - White/Caucasian/European Heritage | 100 |
| Race — Mixed Race | 2 |
Ran from Dec 2006 to primary completion in Dec 2006, 0 months.
Results were first posted in Jan 2018, 11 years 1 month after primary completion.
Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Fluticasone furoate
Rhinitis, Allergic, Perennial →